Dr. Sulaiman Al Habib Medical Services Group Valuation
Is 4013 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4013 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4013 (SAR271.4) is trading below our estimate of fair value (SAR369.5)
Significantly Below Fair Value: 4013 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4013?
Key metric: As 4013 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4013's PE Ratio? | |
|---|---|
| PE Ratio | 42.7x |
| Earnings | ر.س2.23b |
| Market Cap | ر.س94.99b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.5x |
| Enterprise Value/EBITDA | 38.8x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does 4013's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33x | ||
4002 Mouwasat Medical Services | 27.7x | 16.6% | ر.س18.2b |
4004 Dallah Healthcare | 31.4x | 14.2% | ر.س14.8b |
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 46.3x | 20.0% | ر.س13.3b |
4005 National Medical Care | 26.5x | 11.5% | ر.س7.3b |
4013 Dr. Sulaiman Al Habib Medical Services Group | 42.7x | 14.7% | ر.س95.0b |
Price-To-Earnings vs Peers: 4013 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the peer average (33x).
Price to Earnings Ratio vs Industry
How does 4013's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4013 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the Asian Healthcare industry average (21x).
Price to Earnings Ratio vs Fair Ratio
What is 4013's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 42.7x |
| Fair PE Ratio | 37.5x |
Price-To-Earnings vs Fair Ratio: 4013 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the estimated Fair Price-To-Earnings Ratio (37.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س271.40 | ر.س299.90 +10.5% | 9.2% | ر.س347.00 | ر.س245.00 | n/a | 10 |
| Nov ’25 | ر.س286.20 | ر.س301.90 +5.5% | 9.5% | ر.س347.00 | ر.س245.00 | n/a | 10 |
| Oct ’25 | ر.س295.40 | ر.س302.67 +2.5% | 9.9% | ر.س347.00 | ر.س245.00 | n/a | 9 |
| Sep ’25 | ر.س303.40 | ر.س301.56 -0.6% | 10.1% | ر.س347.00 | ر.س245.00 | n/a | 9 |
| Aug ’25 | ر.س284.00 | ر.س292.44 +3.0% | 7.8% | ر.س323.00 | ر.س245.00 | n/a | 9 |
| Jul ’25 | ر.س283.00 | ر.س295.60 +4.5% | 8.5% | ر.س330.00 | ر.س245.00 | n/a | 10 |
| Jun ’25 | ر.س268.20 | ر.س287.10 +7.0% | 13.2% | ر.س330.00 | ر.س200.00 | n/a | 10 |
| May ’25 | ر.س311.00 | ر.س290.31 -6.7% | 14.1% | ر.س345.00 | ر.س200.00 | n/a | 10 |
| Apr ’25 | ر.س309.00 | ر.س284.31 -8.0% | 15.9% | ر.س345.00 | ر.س200.00 | n/a | 10 |
| Mar ’25 | ر.س329.40 | ر.س280.01 -15.0% | 15.5% | ر.س345.00 | ر.س200.00 | n/a | 10 |
| Feb ’25 | ر.س292.80 | ر.س275.91 -5.8% | 15.9% | ر.س345.00 | ر.س200.00 | n/a | 10 |
| Jan ’25 | ر.س288.20 | ر.س262.70 -8.8% | 13.5% | ر.س330.00 | ر.س200.00 | n/a | 10 |
| Dec ’24 | ر.س282.00 | ر.س256.00 -9.2% | 12.6% | ر.س300.00 | ر.س200.00 | n/a | 10 |
| Nov ’24 | ر.س257.00 | ر.س249.44 -2.9% | 12.4% | ر.س300.00 | ر.س200.00 | ر.س286.20 | 9 |
| Oct ’24 | ر.س240.40 | ر.س246.22 +2.4% | 12.9% | ر.س300.00 | ر.س200.00 | ر.س295.40 | 9 |
| Sep ’24 | ر.س243.00 | ر.س255.13 +5.0% | 12.5% | ر.س300.00 | ر.س210.00 | ر.س303.40 | 8 |
| Aug ’24 | ر.س284.60 | ر.س258.56 -9.2% | 11.7% | ر.س300.00 | ر.س210.00 | ر.س284.00 | 9 |
| Jul ’24 | n/a | ر.س258.56 0% | 11.7% | ر.س300.00 | ر.س210.00 | ر.س283.00 | 9 |
| Jun ’24 | ر.س262.00 | ر.س252.57 -3.6% | 11.1% | ر.س295.00 | ر.س210.00 | ر.س268.20 | 7 |
| May ’24 | ر.س293.80 | ر.س243.25 -17.2% | 14.3% | ر.س295.00 | ر.س193.00 | ر.س311.00 | 8 |
| Apr ’24 | ر.س291.40 | ر.س233.88 -19.7% | 16.0% | ر.س270.00 | ر.س180.00 | ر.س309.00 | 8 |
| Mar ’24 | ر.س237.00 | ر.س231.14 -2.5% | 17.0% | ر.س270.00 | ر.س180.00 | ر.س329.40 | 7 |
| Feb ’24 | ر.س240.20 | ر.س216.73 -9.8% | 18.3% | ر.س270.00 | ر.س174.10 | ر.س292.80 | 7 |
| Jan ’24 | ر.س222.80 | ر.س216.73 -2.7% | 18.3% | ر.س270.00 | ر.س174.10 | ر.س288.20 | 7 |
| Dec ’23 | ر.س234.00 | ر.س216.73 -7.4% | 18.3% | ر.س270.00 | ر.س174.10 | ر.س282.00 | 7 |
| Nov ’23 | ر.س226.80 | ر.س199.16 -12.2% | 15.0% | ر.س265.00 | ر.س174.10 | ر.س257.00 | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.